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        Persistent viral infections such as HIV, hepatitis 
B virus (HBV), and hepatitis C virus (HCV) in 
humans, simian immunodefi  ciency virus (SIV) 
in monkeys, and lymphocytic choriomeningi-
tis virus (LCMV) in mice are associated with 
functional exhaustion of virus-specifi  c CD8  +   T 
cells (  1  –  3  ). This defect in responding T cells is 
one of the primary reasons for the inability of 
the host to eliminate the persisting pathogen. 
Because many chronic viral infections cannot 
be cleared by antiviral therapy alone (  4, 5  ), 
therapeutic vaccination, which aims to enhance 
the patient  ’  s own antiviral immune response, 
has been considered as an alternative therapy. 
However, the effi   cacy of such strategies has so 
far been disappointing (  6  –  9  ). Recent work sug-
gests that the decreased proliferative potential 
of virus-specifi  c CD8  +   T cells generated dur-
ing chronic infection, and high viral load at the 
time of vaccination might explain the ineffi   -
cient responses to therapeutic vaccination (  6, 8, 
10  –  12  ). Thus, it is important to develop a thera-
peutic vaccine strategy to more eff  ectively boost 
endogenous T cell responses to control persis-
tent viral infections. 
  We have recently demonstrated that ex-
hausted virus-specifi  c CD8  +   T cells up-regu-
late the inhibitory programmed death-1 (PD-1) 
during chronic infection with LCMV clone-13 
(CL-13) (  13  ). Furthermore, in vivo blockade 
of PD-1 restores the function of virus-specifi  c 
CD8  +   T cells, resulting in enhanced viral clear-
ance. Similarly, virus-specifi  c CD8  +   T cells sig-
nifi  cantly up-regulate PD-1 expression during 
chronic infections such as HIV (  14  –  17  ), HCV 
(  18  –  20  ), and HBV in humans (  21  ) and SIV in 
monkeys (  22  ). This expression correlates with 
viral load in the blood plasma in HIV-infected 
patients (  14, 16, 17  ) and SIV-infected monkeys 
(  22, 23  ). Strikingly, blocking the interaction 
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  Therapeutic vaccination is a potentially promising strategy to enhance T cell immunity and 
viral control in chronically infected individuals. However, therapeutic vaccination ap-
proaches have fallen short of expectations, and effective boosting of antiviral T cell re-
sponses has not always been observed. One of the principal reasons for the limited success 
of therapeutic vaccination is that virus-specifi  c T cells become functionally exhausted 
during chronic infections. We now provide a novel strategy for enhancing the effi  cacy of 
therapeutic vaccines. In this study, we show that blocking programmed death (PD)-1/PD-L1 
inhibitory signals on exhausted CD8  +   T cells, in combination with therapeutic vaccination, 
synergistically enhances functional CD8  +   T cell responses and improves viral control in mice 
chronically infected with lymphocytic choriomeningitis virus. This combinatorial therapeutic 
vaccination was effective even in the absence of CD4  +   T cell help. Thus, our study defi  nes a 
potent new approach to augment the effi  cacy of therapeutic vaccination by blocking 
negative signals. Such an approach may have broad applications in developing treatment 
strategies for chronic infections in general, and perhaps also for tumors. 544 THERAPEUTIC VACCINATION COMBINED WITH PD-L1 BLOCKADE | Ha et al.
Importantly, combinatorial therapeutic vaccination (VV/GP33 + 
     PD-L1) induced a signifi  cant increase in the D  b  GP33-spe-
cifi  c CD8  +   T cell population (P   <   0.01, 2 wk after therapy) 
over that in VV/WT +      PD-L1 mice (  Fig. 1 A  ). This was 
sustained even after cessation of the      PD-L1 treatment. In con-
trast, D  b  GP276-specifi  c CD8  +   T cell responses were not en-
hanced after combinatorial therapeutic vaccination compared 
with PD-L1 blockade of VV/WT-treated mice. Thus, vacci-
nation with VV/GP33 enhanced CD8  +   T cell response specifi  c 
to gp33, but not gp276, indicating epitope-specifi  c responses 
to therapeutic vaccination (  Fig. 1 B  ). Mice receiving combi-
natorial therapeutic vaccination showed accelerated clearance 
of virus from the blood compared with      PD-L1  –  treated 
mice vaccinated with VV/WT (P   <   0.01, 2 wk and 3 wk 
after therapy; P   <   0.05, 4 wk after vaccination;   Fig. 1 C  ). 
Conversely, 75% of VV/WT- and 50% of VV/GP33-vaccinated 
mice remained viremic by 4 wk after vaccination. These re-
sults demonstrate that a combination of therapeutic vaccine 
and PD-L1 blockade synergistically enhanced expansion of 
CD8  +   T cells and promoted clearance of persisting virus dur-
ing chronic infection. 
  To examine whether combinatorial therapeutic vaccina-
tion resulted in increased responses in the tissues, we analyzed 
D  b  GP33-specifi  c CD8  +   T cell responses in diff  erent tissues 
2 wk after vaccination. In nonlymphoid tissues, such as liver 
and lung, as well as in lymphoid tissues, including spleen and 
LN, the combination of PD-L1 blockade with therapeutic 
vaccination resulted in a signifi  cant increase in D  b  GP33-
specifi  c CD8  +   T cells compared with control VV/WT vacci-
nation, as well as VV/WT +      PD-L1 (P   <   0.05 in all tissues 
examined;   Fig. 2, A and B  ).   VV/GP33 therapeutic vaccina-
tion alone did not increase numbers of D  b  GP33-specifi  c 
CD8  +   T cells in the tissues (P   >   0.05), which is consistent 
with our previous study (  11  ). Importantly, there was no 
comparable increase in D  b  GP276-specifi  c CD8  +   T cells be-
tween PD-L1 blockade and combinatorial therapeutic vaccine 
groups, confi  rming that the synergistic eff  ect on expansion of 
CD8  +   T cells was epitope specifi  c (  Fig. 2 C  ). 
  The aforementioned results suggested that PD-L1 block-
ade enhanced epitope-specifi  c responses to therapeutic vac-
cination by rejuvenating circulating exhausted CD8  +   T cells. 
Next, we assessed whether expansion of the D  b  GP33-spe-
cifi  c CD8  +   T cells after combinatorial therapeutic vaccination 
enhanced viral control in these tissues. Mice vaccinated 
with VV/GP33 alone demonstrated a reduction in viral 
titers in the tissues (  Fig. 3 A  ; P   <   0.05 in all tissues), despite 
no detectable increase in D  b  GP33-specifi  c T cells in these 
mice (  Fig. 2, A and B  ).   This suggests that therapeutic vac-
cination may lead to qualitative changes to the antigen-
specifi  c CD8  +   T cells. As expected, PD-L1 blockade of 
VV/WT-vaccinated mice improved viral control (  Fig. 3 A  ; 
P   <   0.05 in all tissues). Importantly, combinatorial thera-
peutic vaccination induced a greater reduction in viral load 
in tissues including spleen, liver, lung, and LN as early as 
2 wk after vaccination compared with the other treatment 
groups (  Fig. 3 A  ; P   <   0.05 in all tissues). Moreover, the 
between PD-1 and its ligands in vitro partially restored eff  ec-
tor function and improved the proliferative capacity of ex-
hausted CD8  +   T cells in these chronic infections (  14  –  23  ). 
Collectively, these data suggest that PD-1 signaling on T cells 
is a major inhibitory pathway operating during chronic infec-
tion and blockade in vivo may be useful for the treatment of 
chronic viral infections. 
  In this study, we examined whether blockade of the PD-1 
pathway in combination with therapeutic vaccination could 
enhance CD8  +   T cell immunity and resolution of a chronic 
infection in mice. Mice that were persistently infected with 
LCMV CL-13 were vaccinated with a recombinant vaccinia 
virus expressing the LCMV gp  33-41   epitope and treated with 
anti  –  PD-L1 blocking antibody. This combinatorial thera-
peutic vaccination synergistically enhanced epitope-specifi  c 
CD8  +   T cell responses and resulted in accelerated viral clear-
ance. Responding CTL demonstrated increased cytokine 
production, increased expression of the interleukin-7 recep-
tor-      (CD127) and decreased expression of PD-1, correlat-
ing with enhanced viral control. Moreover, therapeutic 
vaccination combined with PD-L1 blockade also enhanced 
CD8  +   T cell responses and viral control in the absence 
of CD4  +   T cells. Together, this provides a promising strat-
egy for the treatment of chronic viral infections, including 
those that induce pronounced CD4  +   T cell defi  ciency, such 
as HIV. 
    RESULTS   
  PD-L1 blockade synergizes with therapeutic vaccination 
to enhance T cell immunity and clearance of persistent 
viral infection 
  To determine the eff  ect of therapeutic vaccination in combi-
nation with PD-L1 blockade during chronic infection, mice 
were infected with LCMV CL-13. 4 wk after infection, 
when viral loads were between     10  3   and 10  5   PFU/ml of 
  serum, mice were vaccinated with a recombinant vaccinia 
virus expressing the LCMV gp  33-41   CD8  +   T cell epitope 
(VV/GP33). For the combinatorial therapeutic vaccination, mice 
were treated with anti  –  PD-L1 blocking antibody (     PD-L1) 
after vaccination. Control mice were vaccinated with WT 
vaccinia virus (VV/WT) with or without PD-L1 blockade. 
This experimental setting allowed us to follow antigen-
specifi  c CD8  +   T cell responses to the therapeutic vaccine 
(gp33-specifi  c) alongside responses to other LCMV epitopes 
not found within the vaccine vector (gp276-specifi  c). 
  We longitudinally monitored individual mice for D  b  GP33- 
and D  b  GP276-specifi  c T cell responses, as well as serum viral 
load in the blood after treatment. Consistent with our previ-
ous study (  11  ), therapeutic vaccination (VV/GP33) induced 
little expansion of the D  b  GP33-specifi  c CD8  +   T cell popula-
tion (  Fig. 1 A  ; P   >   0.05, 2 wk after vaccination) and no 
change in gp276 responses (  Fig. 1 B  ), compared with control 
VV/WT vaccinated mice.   PD-L1 blockade of control mice 
(VV/WT +      PD-L1) resulted in a signifi  cant increase of both 
D  b  GP33- and D  b  GP276-specifi  c CD8  +   T cell response (P   <   
0.01 in both, 2 wk after therapy), as previously reported (  13  ). JEM VOL. 205, March 17, 2008 
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combination therapy is durable to a later time point and 
better than PD-L1 blockade alone. 
  To further examine the resolution of viremia after thera-
peutic vaccination, we performed immunostaining on tissue 
sections from the spleen at 2 wk after therapy (  Fig. 3 D  ). 
LCMV CL-13 antigen was found in the marginal zones of 
the white pulp and associated with vasculature in the spleen 
after control VV/WT vaccination. We observed similar viral 
antigen staining after vaccination with VV/GP33, whereas 
PD-L1 blockade appeared to induce clearance from the splenic 
parenchyma, although antigen remained associated with vas-
culature. Moreover, the combination of PD-L1 blockade and 
therapeutic vaccination induced a noticeably greater reduction 
in viral antigen in the spleen. A similar pattern of viral antigen 
mice completely controlled viremia in spleen and liver 
within 4 wk after combinatorial therapeutic vaccination, 
whereas 70 and 60% of VV/GP33-vaccinated mice re-
mained viremic in spleen and liver, respectively, at this time 
point (  Fig. 3 B  ). We also measured viral titers at a later time 
point (14 wk after therapy) to confi  rm the effi   cacy of com-
bined therapy. The kidney is a heavy reservoir of CL-13 
infection and is a good target organ to monitor long-term 
persistence (  3  ). There were high levels of virus in the kid-
ney of CL-13  –  infected mice treated with control vaccine 
(  Fig. 3 C  ). In contrast, mice given the combinatorial thera-
peutic vaccine showed a substantial decrease of virus (P   <   
0.01 and P   <   0.05 compared with VV/WT and VV/WT +   
     PD-L1 groups, respectively), indicating that the effi   cacy of 
    Figure 1.     Synergistic effect of PD-L1 blockade and therapeutic vaccination on T cell responses and viral control.  LCMV  CL-13 – infected  mice 
were vaccinated with wild-type vaccinia virus (VV/WT) or LCMV GP33-41 epitope-expressing vaccinia virus (VV/GP33) at 4 wk after infection (vertical line). 
Cohorts of mice were also treated for 12 d with      PD-L1, starting at 4 wk after infection (shaded region). The number of D  b  GP33-41 (A) and D  b GP276-286 
tetramer-positive cells (B) or viral titer (C) was determined in the blood at the indicated time points. The numbers of D  b GP33-41  tetramer-specifi  c CD8  +   T 
cells and viral titers from individual mice are depicted on the left in A and C. Dashed lines represent virus detection limit. Results are pooled from three 
independent experiments.     546 THERAPEUTIC VACCINATION COMBINED WITH PD-L1 BLOCKADE | Ha et al.
that therapeutic vaccination can improve CD8  +   T cell func-
tion in an epitope-specifi  c manner because IFN-      produc-
tion and CD107a/b expression by CD8  +   T cells responding 
to other epitopes were not increased. PD-L1 blockade in-
duced an increase in functional CD8  +   T cells responding to 
multiple epitopes, as previously reported (  13  ). Importantly, 
combinatorial therapeutic vaccination signifi  cantly increased 
the proportion of IFN-       +   CD107a/b  +   GP33-specifi  c CD8  +   
T cells over that in all other groups (  Fig. 4, A and B  ; P   <   0.01). 
An increase in IFN-      production responding to GP33 pep-
tide appeared to be correlated to viral titer observed in tissues 
(  Fig. 3  ), which is consistent with the study confi  rming the 
critical role of IFN-      in reducing viral loads (  24  ). No such 
increase was seen in CD8  +   T cells responding to other epi-
topes (P   >   0.05). 
  To further determine whether combinatorial therapeu-
tic vaccination improved CD8  +   T cell function, we assessed 
staining was also observed in the liver in the diff  erent treatment 
groups (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20071949/DC1). 
  Functional and phenotypic changes in exhausted CD8  +   
T cells after combinatorial therapeutic vaccination 
  We next determined whether the combination of PD-L1 
blockade with therapeutic vaccine improved the function of 
epitope-specifi  c  CD8  +   T cells during persistent infection. 
We measured the ability of virus-specifi  c CTLs to produce 
the cytokine IFN-      and to degranulate by monitoring 
CD107a/b expression at 2 wk after therapy (  Fig. 4, A and B  ).   
Although therapeutic vaccination alone enhanced few 
D  b  GP33-specifi  c CD8  +   T cell numbers (  Fig. 2  ), IFN-      pro-
duction and CD107a/b expression by CD8  +   T cells specifi  c 
for GP33 was increased compared with control VV/WT-
vaccinated mice (  Fig. 4, A and B  ; P   <   0.05). This indicates 
    Figure 2.     Expansion of epitope-specifi  c CD8  +   T cells in multiple tissues.   (A) The frequency and total number of D  b  GP33-41 (B) and D  b GP276-286 
(C) tetramer-positive cells in the indicated tissues at 2 wk after therapy. Data are representative of two independent experiments.   n   = 3 mice per group in 
each experiment. Results are pooled from two experiments. *, P   <   0.05; **, P   <   0.01.     JEM VOL. 205, March 17, 2008 
ARTICLE
547 
that the combination of therapeutic vaccination and PD-L1 
blockade greatly improved CD8  +   T cell function during chronic 
viral infection. 
  Granzyme B expression on D  b  GP33  +   CD8  +   T cells in 
the blood was gradually down-regulated in control VV/
WT-vaccinated mice as serum viremia decreased (  Fig. 5 A  ).   
The MFI of granzyme B was lower in both blood and 
spleen in mice treated with      PD-L1, with or without 
therapeutic vaccination (P   <   0.01). This decreased gran-
zyme B expression was observed on D  b  GP276  +  , as well as 
D  b  GP33  +  , CD8  +   T cells after PD-L1 blockade alone and 
combinatorial therapeutic vaccination (  Fig. 5 A  ). Impor-
tantly, PD-1 expression on GP33-specifi  c CD8  +   T cells 
was signifi  cantly down-regulated in the spleen, liver, and 
lung in mice treated with the combinatorial vaccine, in 
comparison with the other groups (  Fig. 5 B  ). Decreased 
level of PD-1 after combinatorial therapeutic vaccination 
was also observed on D  b  GP276  +   CD8  +   T cells (  Fig. 5 B  ). 
the ability of IFN-       –  producing CD8  +   T cells to produce 
TNF-      on a per cell basis (  Fig. 4 C  ). After stimulation with 
GP33 peptide, but not with GP276 peptide, the population 
of TNF-       +   IFN-       +   CD8  +   T cells increased in VV/GP33 
vaccinated mice compared with VV/WT mice (P   <   0.05). 
PD-L1 blockade enhanced TNF-      production by GP33- 
and GP276-specifi  c CD8  +   T cells (P   <   0.01). Combinato-
rial therapeutic vaccination further improved the ability of 
IFN-       –  producing CD8  +   T cells to produce TNF-      in re-
sponse to GP33 peptide (P   <   0.05), but not to GP276 
peptide (P   >   0.05). In addition, we observed that IL-2 
production specifi  c to GP33 peptide was improved in the 
mice vaccinated with VV/GP33 +      PD-L1 (20- and 2.5-
fold compared with VV/WT and VV/WT +      PD-L1, re-
spectively), even though the percentage of IL-2/IFN-      
coproducers among IFN-       –  producing CD8  +   T cells did not 
dramatically increase compared with that of PD-L1 block-
ade alone (  Fig. 4 D  ). Together, these results demonstrate 
    Figure 3.     Enhanced viral control in tissues after combinatorial therapeutic vaccination.   (A) Viral titers in the indicated tissues at 2 wk 
after therapy. Dashed lines represent virus detection limit. (B) Percentage of mice containing virus above detectable limit in different tissues at 
4 wk after therapy. (C) Viral titers in the kidney at a later time point (14 wk after therapy).   n   = 6 mice per group. Results are pooled from two ex-
periments. ns, P   >   0.05; *, P   <   0.05; **, P   <   0.01. (D) Immunostaining of spleen with ERTR7 (green) and      LCMV antigens (red) at 2 wk after therapy. 
Bar,  100   μ m.   548 THERAPEUTIC VACCINATION COMBINED WITH PD-L1 BLOCKADE | Ha et al.
of CD127 on a population of D  b  GP33  +   CD8  +   T cells in 
the spleen after      PD-L1 treatment (  Fig. 5 C  ; P   <   0.05). 
The combination of therapeutic vaccine with PD-L1 
blockade did not further increase this CD127  hi   population. 
We also found that CD127 expression in other tissues includ-
ing liver, lung, and LN increased after PD-L1 blockade re-
gardless of therapeutic vaccination. However, combinatorial 
therapeutic vaccination did not induce CD62L expression 
on these cells (Fig. S3, available at http://www.jem.org/cgi/
content/full/jem.20071949/DC1). 
Collectively, reduced expression of granzyme B and PD-1 
tightly correlated with reduced viral titer after combinato-
rial therapeutic vaccination (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20071949/DC1). 
  Exhausted CD8  +   T cells generated during persistent in-
fection display a very diff  erent phenotype from long-lived 
memory cells. Chronically stimulated CD8  +   T cells down-
regulate IL-7R      (CD127), which is indicative of reduced 
responsiveness to prosurvival/homeostatic signals delivered 
by IL-7 (  16, 19, 20, 25  –  27  ). We observed increased expression 
    Figure 4.     Function of exhausted CD8  +   T cells after therapeutic vaccination and PD-L1 blockade.  (A)  IFN-     production and degranulation by 
CD8  +   T cells in vaccinated mice at 2 wk after therapy. Splenocytes were stimulated with the indicated peptides in the presence of     CD107a/b  antibodies, 
and then costained for IFN-     . The cells shown in plots are gated on CD8  +   T cells. (B) The percentages of IFN-     + CD107 +   CD8 +   T cells specifi  c for each of the 
LCMV peptides from A are summarized for multiple mice (  n   = 6 per group). TNF-      (C) and IL-2 (D) production by IFN-     +   CD8 +   T cells in vaccinated mice at 
2 wk after therapy. Splenocytes were stimulated with GP33-41 or GP276-286 peptides. Percentages of cytokine-producing cells among CD8  +   T cells are 
shown in the plots and numbers in parentheses on plots indicate the percentages of cytokine coproducers out of the total IFN-     +   population. 
(C, right) Summarizes the data for multiple mice (  n   = 6 for each response). *, P   <   0.05; **, P   <   0.01.     JEM VOL. 205, March 17, 2008 
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    Figure 5.     Phenotypic changes in antigen-specifi  c CD8  +   T cells after combinatorial therapeutic vaccination.   (A) Expression of granzyme B on 
D  b  GP33-41 tetramer-positive cells in PBMC at the indicated times after therapy and on D  b  GP33-41 or D  b  GP276-286 tetramer-positive cells in spleen at 
4 wk after therapy. Open histograms, granzyme B; fi  lled histograms, isotype control. Numbers represent mean fl  uorescence intensity of granzyme B ex-
pression. PD-1 expression on D  b  GP33-41 or D  b  GP276-286 tetramer-positive cells (B) and CD127 expression on D  b  GP33-41 tetramer-positive cells (C) in 
different tissues at 4 wk after therapy. Numbers represent the frequency of tetramer-positive cells expressing CD127 or PD-1. The data are representative 
of two independent experiments.     550 THERAPEUTIC VACCINATION COMBINED WITH PD-L1 BLOCKADE | Ha et al.
ment enhanced the survival of the antigen-specifi  c CD8  +   T 
cells. Interestingly, this increase in viable (annexin V  -   PI  -  ) 
cells was further increased among D  b  GP33  +   CD8  +   T cells, but 
not D  b  GP276  +   CD8  +   T cells, in mice receiving combinato-
rial therapy, compared with mice treated with      PD-L1 alone 
(  Fig. 6 C  ; P   <   0.02). These data suggest that the increased 
population of epitope-specifi  c CD8  +   T cells after combinato-
rial therapeutic vaccination may result from both increased 
proliferation and decreased susceptibility to cell death. 
  We next measured the eff  ect of combinatorial therapeutic 
vaccination on the ability of epitope-specifi  c CD8  +   T cells to 
produce IFN-      and to induce degranulation in the absence of 
CD4  +   T cell help. A signifi  cant increase of IFN-      production 
and CD107a/b expression was observed after combinatorial 
therapeutic vaccination (  Fig. 6 D  ). Interestingly, increased de-
granulation was also observed in mice treated with VV/GP33 
or PD-L1 blockade alone, although to a lesser extent. How-
ever, combinatorial therapy did not further improve IFN-      
production by D  b  GP33  +   CD8  +   T cells when compared with 
PD-L1 blockade alone (  Fig. 6 E  ), unlike that in the presence of 
CD4  +   T cell help (  Fig. 4 C  ). Similarly, therapeutic vaccination 
did not increase IFN-      production by CD8  +   T cells compared 
with control vaccination. Nevertheless, the clearance of virus 
in these mice correlated with their degranulation capacity. 
Thus, we observed a signifi  cant reduction in virus titer in the 
spleen, liver, and lung after VV/GP33 +      PD-L1 treatment 
compared with therapeutic vaccination or PD-L1 blockade 
alone (  Fig. 6 F  ; P   <   0.05 in multiple tissues). These results 
demonstrate that the combination of therapeutic vaccination 
and PD-L1 blockade more effi   ciently enhanced CD8 + T cell 
responses and viral control than PD-L1 blockade alone, both 
in CD4  +   T cell help  –  suffi   cient and   –  defi  cient hosts. 
  Effect of therapeutic vaccination on antigen presentation 
by dendritic cells 
  Mice chronically infected with LCMV CL-13 contain high 
levels of virus in multiple tissues, and there is clearly suffi   cient 
antigen in these mice to drive virus-specifi  c T cell responses 
(  29  ), especially after blockade of the PD-1  –  PD-L1 pathway 
(  13  ). It is unlikely that the amount of gp33-41 epitope 
expressed in vivo by the recombinant VV/GP33 would ex-
ceed the total amount of gp33-41 epitope present in the 
chronically infected mice. This raised the interesting question 
as to how therapeutic vaccination can provide synergism 
with PD-L1 blockade even if therapeutic vaccination itself 
seems to be ineff  ective. Because CD8  +   T cells specifi  c for 
LCMV epitopes that were not expressed by the vaccine (i.e., 
D  b  GP276-286 tetramer-positive cells) were not boosted after 
therapeutic vaccination, as shown in   Fig. 6 A  , it is likely that 
vaccine-induced infl  ammation alone is not suffi   cient to en-
hance the CD8  +   T cell response. Thus, we hypothesized that 
APCs after therapeutic vaccination can present antigen more 
effi   ciently compared with the APCs present in the chroni-
cally infected mice. To test this, we determined whether 
antigen presentation by APCs is improved after therapeutic 
vaccination during chronic infection. DCs were isolated from 
  Effi  cacy of combinatorial therapeutic vaccination 
in the absence of CD4  +   T cells 
  Under such   “  helpless  ”   conditions, chronic CL-13 infection 
leads to more pronounced exhaustion of antigen-specifi  c 
CD8  +   T cells and is relevant to persistent infections, such as 
HIV in humans. We examined whether the combination of 
therapeutic vaccination and PD-L1 blockade improved CD8  +   
T cell responses under conditions of CD4  +   T cell defi  ciency. 
In our CD4 helpless model, CD4  +   T cells are only transiently 
depleted (  >  99%) using      CD4 antibody (GK1.5) at the time 
of infection, and CD4  +   T cell numbers return to nearby nor-
mal levels within a month after infection. However, although 
total numbers of CD4  +   T cells are restored at a later time 
point after infection with CL-13, the virus-specifi  c CD4  +   T 
cell response is severely impaired compared with memory 
CD4  +   T cell responses after LCMV acute infection, and is 
hardly recovered even after PD-L1 blockade (Fig. S4, available 
at http://www.jem.org/cgi/content/full/jem.20071949/DC1), 
showing that this model provides a situation where CD4  +   T 
cell help is very restricted for a long period of time. When 
CD4  +   T cell help was absent, therapeutic vaccination with 
VV/GP33 alone induced expansion of epitope-specifi  c CD8  +   
T cells (  Fig. 6, A and B  ; P   <   0.01).   Importantly, combinato-
rial therapeutic vaccination further increased the frequency 
of D  b  GP33-specifi  c CD8  +   T cells in helpless mice at least 
twofold compared with therapeutic vaccination or PD-L1 
blockade alone, in both lymphoid and nonlymphoid tissues 
(  Fig. 6, A and B  ). The number of D  b  GP33  +   CD8  +   T cells 
was approximately sixfold higher in lung and threefold higher 
in spleen and liver, respectively, after combinatorial thera-
peutic vaccination (  Fig. 6 B  ; P   <   0.001). However, there 
was no diff  erence in the frequency of D  b  GP276-specifi  c 
CD8  +   T cells between combinatorial therapeutic vaccination 
and      PD-L1 treatment, indicating epitope-specifi  c CD8  +   
T cell expansion by combinatorial therapeutic vaccination 
(  Fig. 6 A  ; P   >   0.05). 
  To examine in detail how combinatorial therapeutic vacci-
nation increased the epitope-specifi  c CD8  +   T cell popula-
tion, we measured the proliferation of antigen-specifi  c CD8  +   
T cells after therapeutic vaccination by BrdU incorporation 
(  Fig. 6 A  ). After PD-L1 blockade,   >  90% of D  b  GP33  +   and 
80% of D  b  GP276  +   cells incorporated BrdU, as previously re-
ported (  13  ). Combinatorial vaccination also induced a similar 
level of BrdU incorporation. These data suggested that the 
exhausted CD8  +   T cells proliferated after PD-L1 blockade, 
and that this proliferation might be accelerated by simultane-
ous therapeutic vaccination resulting in more D  b  GP33-specifi  c 
CD8  +   T cells (  Fig. 6, A and B  ). 
  Increased expression of PD-1 on CD8  +   T cells during 
chronic infection is also known to be associated with suscep-
tibility to apoptosis upon antigen-specifi  c TCR stimulation 
(  22, 28  ). We found that PD-L1 blockade reduced the fre-
quency of Annexin V  +   propidium iodide (PI)  +   apoptotic cells 
(P   <   0.01), as well as cells in the early stages of apoptosis 
(Annexin V  +   PI        , P   <   0.02) and increased numbers of viable 
Annexin V  -   PI  -   cells (  Fig. 6 C  ). This indicated that this treat-JEM VOL. 205, March 17, 2008 
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vaccination could present antigen more effi   ciently than the 
DCs present in the CL-13  –  infected mice. These results sug-
gest that the mechanism of synergism between therapeutic 
vaccination and PD-L1 blockade could be that DCs can 
effi   ciently present epitopes encoded by therapeutic vaccina-
tion and subsequently reinforce the proliferation of antigen-
specifi  c CD8  +  T cells restored by      PD-L1 treatment. 
spleens of LCMV CL-13  –  infected mice vaccinated with 
VV/WT or VV/GP33 and co-cultured with CFSE-labeled naive 
P14 CD8  +   T cells (D  b  GP33-41  –  specifi  c;   Fig. 7 A  ).   DCs from 
mice given the therapeutic vaccine (VV/GP33) were able to 
induce more proliferation of P14 cells compared with DCs 
from the chronically infected mice given VV/WT (  Fig. 7 B  ). 
These data demonstrate that DCs generated after therapeutic 
    Figure 6.     Combinatorial therapeutic vaccination enhances CD8  +   T cell responses in the absence of CD4  +   T cells.   Mice were depleted of CD4  +   T 
cells, infected with LCMV CL-13, and vaccinated with VV/WT or VV/GP33 at 7  –  10-wk after infection, with or without      PD-L1 treatment. 2 wk after treat-
ment, mice were killed for analysis. (A) BrdU incorporation in different tissues. The ratio of BrdU-negative and -positive cells on D  b GP33-41  tetramer-
positive cells and the frequency of tetramer-positive cells are shown on plots. (B) Total number of D  b  GP33-41 tetramer-positive cells in different tissues. 
(C) Live/dead analysis of D  b  GP33-41 tetramer-positive cells in spleen by Annexin V and PI staining. (D) IFN-      and CD107 expression by GP33-specifi  c CD8  +  
T cells in the spleen after treatment. (E) Proportion GP33-specifi  c CD8  +   T cells producing IFN-      in the spleen. (F) Viral titers in the indicated tissues. All 
plots are representative of two experiments and summarized results are pooled from two experiments (  n   = 6 mice per group). *, P   <   0.05; **, P   <   0.01.     552 THERAPEUTIC VACCINATION COMBINED WITH PD-L1 BLOCKADE | Ha et al.
ity, emergence of drug resistance mutations, and rebounding 
viremia after cessation of antiviral therapy (  32  –  34  ). In these 
circumstances, our approach using      PD-L1 might minimize 
a deleterious eff  ect on T cells, maximizing a therapeutic ef-
fect. As shown in our results, therapeutic vaccination most 
effi   ciently boosted epitope-specifi  c CD8  +   T cells when com-
bined with PD-L1 blockade. Expansion of epitope-specifi  c 
CD8  +   T cells and accelerated control of virus were also 
observed in multiple tissues in epitope-specifi  c manner, indi-
cating that the eff  ectiveness of combinatorial therapeutic vac-
cination is valid systemically. Such an approach could be 
more eff  ective in reducing viral load when multiple epitopes 
are introduced to therapeutic vaccine vector. 
  Recent studies of HIV infection showed that PD-1 is sig-
nifi   cantly up-regulated on HIV-specifi  c  CD8  +   T cells in 
blood (  14  –  17  ). Furthermore, the proportion of CD8  +   T cells 
expressing PD-1 and the levels of PD-1 on HIV-specifi  c 
T cells strongly correlated with viral load in the blood plasma 
(  14, 16  ). Antiretroviral treatment resulted in the dramatic 
decline of plasma viral load, coincident with a decrease in 
the level of PD-1 expression on HIV-specifi  c CD8  +   T cells 
(  14, 16  ). Similarly, Urbani et al. showed that although PD-1 
declined on HCV-specifi  c CD8  +   T cells during recovery, its 
expression remained high when HCV persisted (  20  ). Thus, 
PD-1 expression level appears to be a good indicator of viral 
load and disease progression during persistent infection. In 
this study, we show decreased PD-1 expression on antigen-
specifi  c CD8  +   T cells after combinatorial therapeutic vacci-
nation, which correlated with viral control. PD-1 was also 
down-regulated on D  b  GP276  +   as well as D  b  GP33  +   CD8  +   
T cells, suggesting that down-regulation of PD-1 occurred as 
a consequence of viral control. Nevertheless, PD-1 expres-
sion on gp33-specifi  c CD8  +   T cells in diff  erent tissues was 
not always proportional to virus titer, suggesting that other 
factors in the tissue environment may also aff  ect PD-1 ex-
pression on T cells. 
  PD-1 expression is also associated with altered survival 
and expansion of HIV-specifi  c cells (  14  –  16  ). We show that 
combinatorial therapeutic vaccination induced lower num-
bers of Annexin V  +   gp33-specifi  c T cells, suggesting reduced 
susceptibility to apoptosis and enhanced survival. During 
chronic LCMV infection, antigen-specifi  c CD8  +   T cells 
demonstrate reduced responses to the homeostatic cytokine 
IL-7, and an increased dependence upon antigenic signals for 
survival (  29  ). Recent studies also demonstrate that down-
regulation of CD127 occurs on LCMV-, HIV-, and HCV-
specifi  c CD8  +   T cells (  19, 27, 35  ). Interestingly, CD127 was 
found to be up-regulated on a population of antigen-specifi  c 
CD8  +   T cells after PD-L1 blockade and combinatorial thera-
peutic vaccination, suggesting that CD8  +   T cell diff  erentia-
tion was altered after treatment. Functional programming of 
T cells during persistent infection appears to be an ongoing 
event, rather than restricted to signals acquired during prim-
ing (  36  ). Collectively, our data suggest that combinatorial 
therapeutic vaccination generated CD8  +   T cells with improved 
phenotype and function. 
    DISCUSSION   
  The goal of therapeutic vaccination is to enhance adaptive 
immune responses during persistent infection and to reduce 
the viral burden. However, such strategies are often ham-
pered by the reduced responsiveness and low proliferative 
potential of antigen-specifi  c T cells (  11  ), suggesting the need 
for alternative strategies to enhance immune function during 
chronic infection. In this study, we evaluated the effi   cacy of 
therapeutic vaccination in combination with blockade of the 
inhibitory PD-1 pathway, which plays a role in T cell ex-
haustion during chronic viral infection. Administration of a 
therapeutic vaccine in combination with PD-L1 blockade 
enhanced expansion and improved the function of epitope-
specifi  c CD8  +   T cells in mice persistently infected with LCMV 
CL-13. This combinatorial therapeutic vaccination acceler-
ated viral control compared with therapeutic vaccine only or 
PD-L1 blockade alone. These results defi  ne a novel strategy for 
eff  ective therapeutic vaccination of chronic viral infections. 
  When viral load is high and T cell dysfunction is severe, 
therapeutic vaccination alone is unlikely to be highly benefi  -
cial (  11  ). Indeed, poor responses have been reported for the 
therapeutic vaccination of human HBV carriers (  8  ). Con-
versely, at lower viral loads, when T cell exhaustion is less 
severe, therapeutic vaccination may be more eff  ective (  11  ). 
Studies with nonhuman primates support this concept be-
cause therapeutic vaccination is more eff  ective after antiviral 
therapy of SIV replication (  30, 31  ). Although suppression of 
chronic viral replication using antiviral drugs causes a corre-
sponding increase of T cell activity, it can involve drug toxic-
    Figure 7.     Improved antigen presentation after therapeutic vacci-
nation of chronically infected mice.   (A) Mice chronically infected 
with LCMV CL-13 (7 wk after infection) were vaccinated with VV/WT or 
VV/GP33. 1 d later, DCs were isolated from spleens of both groups of mice 
and co-cultured with CFSE-labeled P14 Thy1.1  + CD8 +   T cells. (B) Prolifera-
tion of P14 cells was analyzed at day 3 (top) and 5 (bottom) after co-culture. 
Data are representative from three different samples. The percentage of cells 
showing more than four divisions is indicated in the top left corner of 
each histogram.     JEM VOL. 205, March 17, 2008 
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    MATERIALS AND METHODS   
  Mice and infections.     4  –  6-wk-old female C57BL/6 mice were purchased 
from The Jackson Laboratory. For infection, mice received 2   ×   10  6   PFU of 
LCMV CL-13 i.v. LCMV titers were determined by plaque assays, as de-
scribed previously (  11  ). All mice were used in accordance with National In-
stitutes of Health and the Emory University Institutional Animal Care and 
Use Committee guidelines. 
  In vivo antibody blockade and therapeutic vaccination.     For thera-
peutic vaccination, 2   ×   10  6   PFU of VV/GP33 as therapeutic vaccine or 
VV/WT as control vaccine was given i.p., as described previously (  11  ). For 
PD-L1 blockade, 200   μ  g of rat anti  –  mouse PD-L1 antibody (10F:9G2) or rat 
IgG2b isotype control were administered i.p. 5 times every 3 d, beginning 
on the day of vaccination. For depletion of CD4  +   T cells, mice were given 
500   μ  g of anti  –  mouse CD4 antibody (GK1.5; BioExpress) i.p. on days      1 
and 0 after infection with CL-13. 
  Cell isolation and in vitro proliferation assay.     Lymphocytes were 
isolated from tissues including spleen, liver, lung, inguinal LN, and blood, 
as previously described (  13  ). Liver and lung were perfused with ice-cold 
PBS before removal for lymphocyte isolation. For DC isolation, spleen 
was digested in complete media containing 1 mg/ml collagenase type II 
(Worthington Biochemicals) and 1 mg/ml DNase (Sigma-Aldrich) as 
previously described (  47  ). DCs were enriched using CD11c beads (Miltenyi 
Biotec). To measure the ability of antigen presentation by DCs, 5   ×   10  5   
P14 Thy1.1  +   CD8  +   T cells labeled with CFSE were cultured with 2.5   ×   
10  4   DCs. Proliferation was determined by fl  ow cytometry after 3 or 5 d 
in culture. 
  Antibodies and fl  ow cytometry.     MHC class I tetramers were generated 
and used as previously described (  3  ). All antibodies were obtained from BD 
Biosciences except for granzyme B (Caltag Laboratories) and CD127 (eBio-
science). All surface and intracellular cytokine staining was performed as pre-
viously described (  3  ). To detect degranulation, splenocytes were stimulated 
for 5 h in the presence of brefeldin, monensin, anti  –  CD107a-FITC, and 
anti  –  CD107b-FITC. For in vivo BrdU incorporation, CL-13  –  infected mice 
were fed 1 mg/ml BrdU in their drinking water every day for 2 wk from the 
time point of therapeutic vaccination. Intracellular staining with a BrdU-
specifi  c antibody was performed as previously described (  48  ). For analysis of 
direct ex vivo apoptosis, splenocytes were isolated and briefl  y incubated with 
Annexin V and PI as previously described (  48  ). 
  Confocal microscopy.     Spleens were removed from mice and frozen in 
OCT (TissueTek). 20-  μ  m cryostat sections were fi  xed in ice-cold acetone 
for 10 min. Sections were stained with ER-TR7 antibody (Biogenesis) and 
goat anti  –  rat Alexa Fluor 488 (Invitrogen) to detect reticular cells, and with 
polyclonal anti-LCMV guinea pig sera plus goat anti  –  guinea pig Alexa Fluor 
568 (Invitrogen). Sections were analyzed by confocal microscopy (LSM510 
Meta; Carl Zeiss, Inc.). Images were prepared using ImageJ (National Insti-
tutes of Health) and Photoshop (Adobe). 
  Quantitative real-time RT-PCR.     Sequences of PCR primer pairs for IL-10 
and HPRT are as follows: IL-10 (forward, 5     -GGTTGCCAAGCCTTATC-
GGA-3     ; reverse, 5     -ACCTGCTCCACTGCCTTGCT-3     ) and HPRT 
(forward: 5     -AGGTTGCAAGCTTGCTGGT-3     ; reverse, 5     -TGAAGTAC-
TCATTATAGTCAAGGGCA-3     ). Total RNA were extracted from whole 
spleens using RNeasy mini kit (QIAGEN), and then reverse transcribed 
by Superscript II (Invitrogen). Real-time quantitative RT-PCR for IL-10 
mRNA using SYBR Green (Applied Biosystems) and detected using an 
iCycler (Bio-Rad Laboratories) as previously described (  47  ). IL-10 expression 
was quantifi  ed, using HPRT as a reference, by the comparative C  T   method, 
as per the manufacturer  ’  s instructions (Applied Biosystems). 
  Statistical analysis.     Statistical analysis was performed with two-tailed un-
paired Student  ’  s   t   tests using Prism (GraphPad Software, Inc.). 
  We also demonstrate that DCs generated after therapeutic 
vaccination with VV/GP33 provide critical positive signals 
that can now synergize with blocking PD-1-mediated nega-
tive signals. It is worth noting that these positive signals from 
DCs require the generation of new peptides from the thera-
peutic vaccine and are not simply caused by some infl  amma-
tion induced by the VV infection because (a) the response 
specifi  c to D  b  GP276-286 epitope was not changed after 
VV/GP33 therapeutic vaccination and (b) LCMV-specifi  c 
CD8  +   T cells were not aff  ected by vaccination with wild-
type vaccinia virus. Indeed, there was no diff  erence in the 
levels of infl  ammatory cytokines (i.e., TNF-     , IFN-     , MCP-1, 
and IL-10) after vaccination with VV/WT or VV/GP33 
(unpublished data). 
  Though therapeutic vaccination alone is not suffi   cient to 
boost the ongoing CD8  +   T cell responses caused by the 
abundance of immunosuppressive signals, blockade of such 
signals may be enough to tip the balance toward positive 
amplifi  cation of the response. Based on this original concept, 
it would be interesting to block other immunosuppressive 
factors in combination with therapeutic vaccination. IL-10 
blockade is one potential candidate because IL-10 is elevated 
during LCMV, HIV, HCV, and HBV infections (  37  –  41  ) 
and its blockade can improve viral clearance (  42, 43  ). We also 
observed that IL-10 mRNA levels are elevated around two-
fold in the mice chronically infected and vaccinated, com-
pared with the naive mice (Fig. S5, available at http://www
.jem.org/cgi/content/full/jem.20071949/DC1), suggesting 
the possibility to increase the effi   cacy of therapeutic vaccine 
when combined with blocking IL-10 signaling. Indeed, 
Brooks et al. (on p. 533 of this issue) demonstrates that 
neutralization of immunosuppressive IL-10 signals can also 
signifi  cantly enhance the effi   cacy of therapeutic vaccination 
(  44  ). Thus, their study, along with ours, establishes that 
blocking immune inhibitory signals might overcome the 
failure of current therapeutic vaccination strategies to treat 
persistent viral infections. Interestingly, in vivo PD-L1 blockade 
does not seem to aff  ect IL-10 level during chronic infection 
(Fig. S5), even though PD-1/PD-L1 blockade has been 
reported to down-regulate IL-10 but up-regulate IL-2 and 
IFN-      during in vitro stimulation (  45, 46  ). These data sug-
gest that inherent suppression on exhausted T cells by PD-1 
and environmental suppression by IL-10 might be regulated 
independently. Thus, it would be interesting to test the 
eff   ect of synergism between PD-1 blockade and IL-10 
blockade on the induction of CD8  +   T cell response during 
chronic infection. 
  In summary, our study shows that therapeutic vaccination 
during chronic viral infection, in combination with PD-L1 
blockade, synergistically boosts epitope-specifi  c CD8  +   T cell 
responses and promotes viral control. These experiments 
demonstrate that blocking this major inhibitory pathway dur-
ing chronic infection improves the effi   cacy of therapeutic 
vaccination. This strategy may prove useful for the treatment 
of persistent infections, in general, as well as to improve im-
mune responses to tumors. 554 THERAPEUTIC VACCINATION COMBINED WITH PD-L1 BLOCKADE | Ha et al.
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